---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-108629"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:21:59.005302+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences reports positive interim Phase 1a results for ABI-5366 in recurrent genital herpes

## Summary
- ABI-5366 was well-tolerated with favorable safety profile and exposure up to 70 days in healthy participants.
- Half-life of approximately 20 days supports both once-weekly and once-monthly oral dosing schedules.
- Screening for Phase 1b in participants with recurrent genital herpes is now underway.
- Interim Phase 1b results are expected in the first half of 2025.
- Single doses of ABI-5366 surpassed target plasma concentrations for antiviral efficacy.

## SEC filing metadata
- accession: 0000950170-24-108629
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017024108629/0000950170-24-108629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017024108629/asmb-20240923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-108629
- JSON: https://secwatch.observer/filing/0000950170-24-108629.json
- Plain text: https://secwatch.observer/filing/0000950170-24-108629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.